返回期刊详情
J
Journal of Bone and Joint Surgery
IF
论文数104
被引数
期刊论文 104
发表时间
Time to Bring Gait Testing to the Clinic Hallway: Commentary on an article by Yuki Nakao, MD, et al.: “: Preoperative Gait Speed as a Predictor of Patient-Reported Outcomes After Total Hip Arthroplasty. Insights from Patient Acceptable Symptom State and K-Means Clustering Analyses: ”是时候将步态测试引入临床走廊了:关于Yuki Nakao, MD等人文章的评论:“全髋关节置换术后患者报告结局的术前步态速度预测因素:来自患者可接受症状状态和K-Means聚类分析的观点。”
JBJS
IF0
AI Disclosure Is a Two-Way Street: Commentary on an article by Josh Major, BS, et al.: “: Exploring the Endorsement and Implementation of Artificial Intelligence Guidelines in Leading Orthopaedic and Sports Medicine Journals. A Cross-Sectional Study: ”AI披露是一条双向车道:对Josh Major, BS等人文章的评论:“探索领先骨科和运动医学期刊中人工智能指南的认可与实施:一项横断面研究。”
JBJS
IF0
Tourniquet or No Tourniquet: What Is the Price to Pay in Primary TKA?: Commentary on article by Fu-Li Peng, PhD, et al.: “: Effect of Tourniquet Use on 3D Cement Penetration and Mid-Term Implant Stability in Primary Total Knee Arthroplasty. A Randomized Controlled Trial: ”止血带或不用止血带:在初次全膝关节置换术中需要付出什么代价?——评 Fu-Li Peng, PhD 等人的文章:“止血带使用对初次全膝关节置换术中3D骨水泥渗透和中期假体稳定性的影响:一项随机对照试验”
JBJS
IF0
Another Defining Number in Knee Pathology Assessment: Commentary on an article by Miho J. Tanaka, MD, PhD, et al.: “: The Ultrasound-Assisted Patellar Glide Test: A Novel Examination Method for Quantifying Patellar Instability: ”膝关节病变评估中的另一个标志性数字:对Miho J. Tanaka, MD, PhD等人文章的评论:“超声辅助髌骨滑动试验:一种用于量化髌骨不稳定的创新检查方法。”
JBJS
IF0
Orthopaedic Surgeons Need to Ask About Intimate Partner Violence: Commentary on an article by Natalie Fleming, MSW, et al.: “: Intimate Partner Violence in a Patient Population with Orthopaedic Trauma. Gender Disparities, Delayed Disclosures, and Poor Clinical Outcomes: ”骨科医生需要询问亲密伴侣暴力:Natalie Fleming, MSW 等人文章的评论:“骨科创伤患者群体中的亲密伴侣暴力。性别差异、延迟披露和不良临床结局:”
JBJS
IF0
Should a Course of Oral Corticosteroids Be Used Routinely After TKA?: Commentary on an article by Supakit Kanitnate, MD, et al.:: “Oral Corticosteroids Reduce Pain After Total Knee Arthroplasty: A Higher Dose of Dexamethasone Effectively Controlled Pain During Motion. A Dose-Response Randomized Placebo-Controlled Trial”
JBJS
IF0
Antioxidant-Loaded Highly Cross-Linked Polyethylene in Total Knee Arthroplasty: The Need for Radiostereometric Randomized Controlled Trials: Commentary on an article by Heather A. Prentice, PhD, et al.: “: Antioxidant-Loaded Highly Cross-Linked Polyethylene May Reduce Revision Risk in Total Knee Arthroplasty. A U.S.-Based Cohort Study: ”
JBJS
IF0
Surgical Treatment of Osteochondritis Dissecans Leading to Normal Bone Density: Commentary on an article by Satoshi Miyamura, MD, PhD, et al.: “: Normalization of Subchondral Bone Density Patterns After Surgical Treatment for Capitellar Osteochondritis Dissecans. A Quantitative Analysis: ”关节骨软骨炎的手术治疗导致正常骨密度:对Satoshi Miyamura, MD, PhD等人文章的评论:“:治疗后肱骨头下骨密度模式的正常化。一项定量分析:”
JBJS
IF0
Malpractice Litigation in Orthopaedic Surgery: Considerations Regarding Subspecialty and Training Level: Commentary on an article by Peter Boufadel, MD, et al.: “: Medical Malpractice Litigation in Orthopaedic Surgery in the United States. Risk Factors, Outcomes, and Strategies for Navigating Lawsuits, Prevention, and Reform: ”骨科手术中的医疗过失诉讼:关于亚专业和培训水平的考虑:Peter Boufadel, MD等人的文章评述:“美国骨科手术中的医疗过失诉讼。风险因素、结果以及应对诉讼、预防和改革的策略:”
JBJS
IF0
The Importance of Phase-2 Clinical Research: Commentary on an article by Weishi Li, MD, PhD, et al.:: “Bezeotermin Alfa (rhBMP-6) Administration in Lumbar Interbody Fusion Surgery Using a Posterior Approach. A Randomized, Double-Blinded, Placebo-Controlled Phase-2 Study”II期临床研究的重要性:对Weishi Li, MD, PhD等人文章的评论::“经后路腰椎椎间融合术中Bezeotermin Alfa (rhBMP-6)的应用。一项随机、双盲、安慰剂对照的II期研究”
JBJS
IF0
To Debride or Not to Debride–That Was the Question: Commentary on an article by Leslie Bisson, MD, et al.: “: Debridement of Unstable Chondral Lesions During Arthroscopic Partial Meniscectomy Provides No Long-Term Benefit. Patient Outcomes 9 Years After the Original ChAMP Trial: ”去坏死还是不去坏死——这才是问题所在:对Leslie Bisson, MD等人文章的评论:“在关节镜下半月板部分切除术期间对不稳定的软骨病变进行去坏死处理并未提供长期益处。原始ChAMP试验9年后的患者结局。”
JBJS
IF0

